Disagreements between central clinical events committee and site investigator assessments of myocardial infarction end- points in an international clinical trial: Review of the PURSUIT study

Current Controlled Trials in Cardiovascular Medicine

Volumn 2, Issue 4, 2001, Pages 187-194

  Mahaffey, Kenneth W ^a   Harrington, Robert A ^a   Akkerhuis, Martijn ^b   Kleiman, Neal S ^c   Berdan, Lisa G ^a   Crenshaw, Brian S ^a   Tardiff, Barbara E ^a   Granger, Christopher B ^a   DeJong, Ingrid ^a   Bhapkar, Manju ^a   Widimsky, Petr ^d   Corbalon, Ramón ^e   Lee, Kerry L ^a   Deckers, Jaap W ^b   Simoons, Maarten L ^b   Topol, Eric J ^f   Califf, Robert M ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c HOUSTON METHODIST HOSPITAL   (United States)

^d CHARLES UNIVERSITY   (Czech Republic)

^e PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^f LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Acute coronary syndromes; Adjudication; Clinical events committee; End points; Myocardial infarction

Indexed keywords

EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEART ENZYME; PLACEBO;

ARTICLE; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE CLASSIFICATION; ELECTROCARDIOGRAM; FATALITY; HEART INFARCTION; HUMAN; INFORMATION; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MORTALITY; MULTICENTER STUDY; ORGANIZATION; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; STANDARD;

EID: 17944380212     PISSN: 14686708     EISSN: None     Source Type: Journal    
DOI: 10.1186/CVM-2-4-187     Document Type: Article

References (24)

1. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
2. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
3. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
4. Collaborative overview of randomised trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
5. Myonecrosis after revascularization procedures
6. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes without persistent ST-segment elevation: A randomized, placebo-controlled, clinical trial
7. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease
8. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention - IMPACT-II
9. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement Trial
10. Outcome assessment for clinical trials: How many adjudicators do we need?
11. Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study
12. Who should code cause of death in a clinical trial?
13. Reliability of death certificate diagnoses
14. Grading diabetic retinopathy from stereoscopic color fundus photographs - An extension of the modified Airlie House classification
15. Bleeding classification in clinical trials: Observer variability and clinical relevance
16. Systematic adjudication of myocardial infarction end-points in an international clinical trial
17. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB trial
18. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
19. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
20. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina - The CAPTURE study
21. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial
22. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
23. Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes: Results from PURSUIT
24. 3 blockade with percutaneous coronary intervention